

## Research Article

# Association between Paraoxonases Gene Expression and Oxidative Stress in Hepatotoxicity Induced by CCl<sub>4</sub>

Mohamed M. Hafez,<sup>1</sup> Othman A. Al-Shabanah,<sup>1</sup> Naif O. Al-Harbi,<sup>1</sup> Mohamed M. Al-Harbi,<sup>1</sup> Salim S. Al-Rejaie,<sup>1</sup> Saad M. Alsurayea,<sup>2</sup> and Mohamed M. Sayed-Ahmed<sup>1</sup>

<sup>1</sup> Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

<sup>2</sup> Riyadh Regional Laboratory and Blood Bank, Riyadh 11451, Saudi Arabia

Correspondence should be addressed to Mohamed M. Hafez; mohhafez\_2000@yahoo.com

Received 13 June 2014; Revised 22 August 2014; Accepted 22 August 2014; Published 17 November 2014

Academic Editor: Liang-Jun Yan

Copyright © 2014 Mohamed M. Hafez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Objectives.** The purpose of the study is to evaluate the hepatoprotective effect of rutin in carbon tetrachloride- (CCl<sub>4</sub>-) induced liver injuries in rat model. **Methods.** Forty male Wistar albino rats were divided into four groups. Group I was the control group and received dimethyl sulphoxide (DMSO) and olive oil. Group II received rutin. Groups III and IV were treated with CCl<sub>4</sub>. Group IV was administered rutin after 48 h of CCl<sub>4</sub> treatment. Liver enzymes level, lipid profile, lipid peroxidation, and hydrogen peroxide were measured. The genes expression levels were monitored by real time RT-PCR and western blot techniques. **Results.** CCl<sub>4</sub> group showed significant increase in alanine aminotransferase (ALT), aspartate aminotransferase (AST), thiobarbituric acid reactive substances (TBAR), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and lipid profile and a significant decrease in glutathione peroxidase (GPx), glutathione S transferase (GST), catalase (CAT), paraoxonase-1 (PON-1), paraoxonase-3 (PON-3), peroxisome proliferator activated receptor delta (PPAR-δ), and ATP-binding cassette transporter 1 (ABAC1) genes expression levels. Interestingly, rutin supplementation completely reversed the biochemical and gene expression levels induced by CCl<sub>4</sub> to control values. **Conclusion.** CCl<sub>4</sub> administration causes aberration of genes expression levels in oxidative stress pathway resulting in DNA damage and hepatotoxicity. Rutin causes hepatoprotective effect through enhancing the antioxidant genes.

## 1. Introduction

Liver is important in regulating metabolic functions and various physiological processes [1]. In addition, it is involved in detoxification of some drugs and xenobiotics which lead to an increase susceptible to the toxicity from these agents [2]. Oxidative stress is correlated with inflammation, cancer, and multiple organ toxicity [3]. Exposure to toxic chemicals can cause hepatocyte injuries through metabolic activation of reactive oxygen species (ROS), such as superoxide, hydroxy radicals, and H<sub>2</sub>O<sub>2</sub> [4]. ROS can induce tissue injury via lipid peroxidation and enhance liver fibrosis by increasing collagen synthesis [5, 6]. Antioxidant enzymes act as free radical scavenging systems and provide first-line defense against ROS such as superoxide dismutase (SOD), CAT, GPx, and nutritional antioxidants [7]. Their role as protective enzymes is well known and is investigated extensively in

in vivo models. CAT and GPx catalyze dismutation of the superoxide anion (O<sup>2-</sup>) to H<sub>2</sub>O<sub>2</sub> and then to water thus providing protection against ROS.

The paraoxonase (PON) gene is a family that contains three members, PON1, PON2, and PON3 [8]. PON1 is synthesized primarily in liver and secreted into plasma and its natural physiological function is metabolism of toxic oxidized lipids of both low density lipoprotein (LDL) and HDL particles [9]. PON3 is predominantly expressed in liver and is associated with HDL. PON1 and PON3 share the lactonase activity and antioxidant property which participate in preventing LDL oxidation [10]. The enzymatic activities of PON1 and PON3 are different [11, 12]. Numerous studies are focused on the relationship between PON1/PON3 and the development of oxidative stress related diseases [13, 14]. PON2 has antioxidant properties and is more widely distributed [10, 15].

Monocyte chemoattractant protein-1 (MCP-1) plays an important role in inflammation by regulating the recruitment of monocytes into tissues and their subsequent differentiation to macrophages [16]. Therefore, its expression increased in chronic inflammatory diseases including liver injury [17, 18]. The MCP-1 overexpression in liver cirrhosis suggests that the protein involved in hepatic injury and fibrosis may downregulate the action of MCP-1 [16].

Carbon tetrachloride is a xenobiotic that is extensively used to study hepatotoxicity in animal models by initiating lipid peroxidation [19]. Bioactivation of phase I cytochrome P450 system induced by  $\text{CCl}_4$  can induce acute and chronic tissue injuries through formation of reactive metabolic trichloromethyl radicals ( $\cdot\text{CCl}_3$ ) and peroxy trichloromethyl radicals ( $\cdot\text{OCCl}_3$ ). Trichloromethyl can react with sulfhydryl groups (glutathione and protein thiols) and antioxidant enzymes such as CAT and SOD. Trichloromethyl-free radicals overproduction enhances the membrane lipid peroxidation, finally leading to liver steatosis, fibrosis, or cirrhosis [20]. These free radicals can covalently bind to macromolecules such as proteins, lipids, and nucleic acids [19, 21].

Polyphenolic compounds such as flavonoids are markedly found in fruits, vegetables, and medicinal plants and play important role in detoxification of free radicals [22, 23]. Rutin, flavonoid glycosides, possesses different protective effects such as antitumor [24], anti-inflammatory [25], antimutagenic [26], and immunomodulating activities [27]; and hepatoprotection against  $\text{CCl}_4$ -induced liver injuries [19]. The present study investigated the hepatoprotective effects of rutin on oxidative stress and inflammation via studying the PON1, PPAR- $\delta$ , and MCP-1 genes expression in hepatotoxic rat model induced by  $\text{CCl}_4$ .

## 2. Materials and Methods

**2.1. Kits and Chemicals.** Carbon tetrachloride and rutin were purchased from Sigma Chemicals Co., USA. TBAR kit was purchased from Cayman Chemical Company (Cayman chemical, MI);  $\text{H}_2\text{O}_2$  kit was purchased from BioVision Company (BioVision, Inc, CA, USA). Gene expression kit was purchased from Applied Biosystems (Applied Biosystems, CA, USA) and synthesized by Metabione Company.

**2.2. Animal.** Six-week-old male Wistar albino rats with average body weight 180–200 gm were obtained from the Animal Care Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. The animals were kept in ordinary cages under standard conditions of temperature ( $22 \pm 1^\circ\text{C}$ ), humidity (50–55%), and a 12 h light/dark. They have free access to standard laboratory feed and water, according to the study protocol. All methods including euthanasia procedure were conducted in accordance with Guide for Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, National Institute of Health (NIH publication no. 80–23; 1996) and it has been approved by Research Ethics Committee of Experimental Animal Care Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

**2.3. Experimental Design.** The experimental design was performed according to Khan et al. [19]. To study the hepatoprotective effects of rutin, a total of 40 adult male Wistar albino rats were used and randomly divided into 4 groups of 10 animals each as follows.

- (i) Group I (control group) received 3 mL/kg olive oil intraperitoneally (Monday and Thursday) and 3 mL/kg DMSO intragastrically using gavage twice a week for four weeks (Saturday and Wednesday).
- (ii) Group II (rutin group) was intragastrically treated with 70 mg/kg rutin in DMSO twice a week for four weeks (Saturday and Wednesday).
- (iii) Group III ( $\text{CCl}_4$  group) was intraperitoneally treated with 3 mL/kg  $\text{CCl}_4$  (30% in olive oil) twice a week (Monday and Thursday) for four weeks.
- (iv) Group IV ( $\text{CCl}_4$ -rutin group) received 70 mg/kg rutin intragastrically, after 48 h of  $\text{CCl}_4$  treatment, twice a week for four weeks (Saturday and Wednesday).

After 24 hours of last treatment protocol, animals were killed by decapitation after exposure to ether, and blood samples were obtained and then serum was separated and kept at  $-80^\circ\text{C}$ . The liver was immediately removed and washed by ice-cold saline solution. A part of liver was shock-frozen in liquid nitrogen and stored at  $-80^\circ\text{C}$  until being used for gene expression analysis.

## 2.4. Bioassay Measurements

**2.4.1. Blood Chemistry.** Serum levels of liver enzymes (AST, ALT), total cholesterol, HDL, and LDL were estimated by using commercially available diagnostic kits (Human, Wiesbaden, Germany).

**2.4.2. Serum Hydrogen Peroxide Concentration.** Serum  $\text{H}_2\text{O}_2$  concentration levels were measured by BioVision assay kit (BioVision, Inc., CA, USA) according to manufacturer's instructions. The principles based on the present of horse radish peroxidase, the OxiRed probe, react with  $\text{H}_2\text{O}_2$  to produce a product with color that can be measured spectrophotometrically.

**2.4.3. Serum Thiobarbituric Acid Reactive Substances.** Lipid peroxidation in serum sample was determined using TBARS assay kit (Cayman Chemical, MI) according to the manufacturer's instructions. Briefly, MDA standard curve was prepared by diluting 250  $\mu\text{L}$  MDA standard with 750  $\mu\text{L}$  water and then serial dilution that started from 0  $\mu\text{m}$  to 50  $\mu\text{m}$  was prepared. A mixture of 100  $\mu\text{L}$  of serum sample, standard and 100  $\mu\text{L}$  of SDS was first prepared. Four mL of color reagent was added to each mixture and boiled for an hour. After that, the reaction was stopped on ice for 10 min and centrifuged for 10 min at 1600  $\times g$ ; then 150  $\mu\text{L}$  of the supernatant was loaded in a 96-well plate and absorbance was read at 540 nm. TBARS concentration was calculated from MDA standard curve.

TABLE 1: The primers used for real time polymerase chain reaction.

Gene	Forward primer	Reverse primer
PON-1	TGAGAGCTTCTATGCCACAAATG	CCATGACAGGCCCAAGTACA
PON-3	CATCCAGGATCCTTTGTTCAGATAA	CACGGTGTGCCCTGAAG
CAT	CGACCGAGGGATTCCAGATG	ATCCGGGTCTTCTGTGCAA
GPx	CGGTTTCCCGTGCAATCAGT	ACACCGGGGACCAAATGATG
GST	GCC TTC TAC CCG AA G ACA CCT T	GTC AGC CTG TTC CCT ACA
MCP-1	TCGCTTCTGACACCATGCA	TGCTACAGGCAGCAAATGTGA
ABCA1	CCCGGCGGAGTAGAAAGG	AGGGCGATGCAAACAAAGAC
PPAR- $\delta$	GCCAAGAACATCCCCAACTTC	GCAAAGATGGCCTCATGCA
GAPDH	AACTCCCATTCCTCCACCTT	GAGGGCCTCTCTTTGCTCT

### 2.5. Detection of Gene Expression Level by Real Time PCR in Liver Tissues

**2.5.1. Total RNA Extraction.** Total RNA was extracted from liver tissues by TRIzol method according to the standard protocol. Briefly, RNA was extracted by homogenization of liver tissues (Polytron; Kinematica, Lucerne, Switzerland) in TRIzol reagent (Invitrogen Life Technologies, UK) at maximum speed for 90–120 s. The homogenate was incubated for 5 min at room temperature. A 1:5 volume of chloroform was added, and the tube was vortexed and subjected to centrifugation at 12,000 g for 15 min. The aqueous phase was isolated, and the total RNA was precipitated by cold absolute ethanol. After centrifugation and washing, the total RNA was finally eluted in 20  $\mu$ L of RNase, DNase free water. The quantity was characterized using a UV spectrophotometer (NanoDrop 8000, Thermo Scientific, USA). The isolated RNA has a 260/280 ratio of 1.9–2.1.

**2.5.2. First-Strand cDNA Synthesis.** First-strand cDNA was synthesized from 1  $\mu$ g total RNA in 20  $\mu$ L by reverse transcription using high capacity cDNA kit (Applied Biosystems, CA, USA) according to the manufacturer's instructions. Reverse transcription reaction consists of 2  $\mu$ L Oligo-dT (50  $\mu$ M), 2  $\mu$ L of 10x reverse transcriptase buffer, 0.8  $\mu$ L of deoxynucleoside triphosphate (25 mM), 1  $\mu$ L of RNase inhibitor (40 U/ $\mu$ L), 1  $\mu$ L of MultiScribe Reverse Transcriptase (50 U/ $\mu$ L), and RNase free dH<sub>2</sub>O, up to a final volume of 20  $\mu$ L. The cDNA was then stored at  $-20^{\circ}\text{C}$  for the gene expression study.

Real time quantitative PCR was performed to detect the gene expression of GPx, CAT, GST, PON1, PON3, PPAR- $\delta$ , MCP-1, and ABCA1 in liver tissue using SYBR master mix (Applied Biosystems, CA, USA) and the reaction was performed on ABI PRISM 7500 Detection System (Applied Biosystems, USA). The program was set to run for one cycle at  $95^{\circ}\text{C}$  for 2 min, followed by 40 cycles at  $95^{\circ}\text{C}$  for 15 s and at  $60^{\circ}\text{C}$  for 1 min. The specificity of PCR amplification was confirmed by agarose gel electrophoresis and melting curve analysis. GAPDH was used as internal control for qRT-PCR. The primers were designed using Primer Express 3.0 software (Applied Biosystems, CA, USA) and listed in Table 1. Results of gene expression were analyzed using  $2^{-\Delta\Delta\text{CT}}$  method. Data

were expressed as the mean fold changes  $\pm$  SEM for three independent amplifications.

**2.6. Western Blot Analysis.** Liver tissues were washed with ice-cold PBS and the protein extracts were prepared using ice-cold cell lyses buffer supplemented with protease inhibitor cocktail (IBI SCIENTIFIC, Peosta, USA). Protein concentrations were measured using Bradford assay (Bio-Rad, CA, USA) according to the manufacturer's protocol. Proteins were separated on 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gels and transferred to nitrocellulose membrane. The membrane was blocked with 5% skimmed milk in TBS-T (10 mM Tris-HCl, 150 mM NaCl, 0.25% Tween 20, pH 7.5) at room temperature for 2 h followed by incubation with 2  $\mu$ g/mL of primary antibody for GPx (sc-22145), CAT (sc-34285), GST (ab19256), PON-1 (sc-59646), PON-3 (sc-21156), PPAR- $\delta$  (ab8937), ABCA-1 (sc-58219), MCP-1 (sc-28879), and GAPDH (sc-32757) diluted in TBS and 5% skimmed milk overnight at  $4^{\circ}\text{C}$ . After washing with TBS-T buffer, the membrane was incubated with 1  $\mu$ g/mL of horseradish peroxidase (HRP) labeled secondary antibody diluted in TBS-T buffer for 2 h at room temperature, followed by three washes with TBS-T buffer. The detection was performed using chemiluminescence assay (Amersham, GE Healthcare, Life Sciences, UK). Membranes were exposed to X-ray film to observe the bands (Kodak, Rochester, NY). Protein bands in treated and untreated (control) groups were quantified using the Kodak Scientific ID software.

**2.7. Statistical Analyses.** Differences between obtained values (mean  $\pm$  SEM,  $n = 10$ ) were carried out by one-way analysis of variance followed by Tukey-Kramer multiple comparison using Graphpad Prism 5 software. The differences were considered statistically significant at  $P < 0.05$ .

## 3. Results

**3.1. The Effect of CCl<sub>4</sub>, Rutin, and Their Combination on Lipid Profile and Liver Enzymes.** ALT and AST serum levels were used as biochemical markers for early acute hepatotoxicity. The CCl<sub>4</sub> group showed significant increase in AST ( $65 \pm 1.2$ ) and ALT ( $72 \pm 2.2$ ) compared to the control group ( $23.5 \pm 1.8$  and  $24.2 \pm 1.3$ , resp.) ( $P < 0.001$ ). The rutin group showed no

TABLE 2: The effect of CCl<sub>4</sub>, rutin, and their combination on lipid profile, TBAR, and H<sub>2</sub>O<sub>2</sub>.

Group	Cholesterol (mg/dL)	Triglycerides (mg/dL)	HDL (mg/dL)	LDL (mg/dL)	TBAR (nmol/mL)	H <sub>2</sub> O <sub>2</sub> (μM)
Control	50 ± 0.33	57.82 ± 1.9	33.4 ± 0.3	38 ± 0.95	18 ± 2.2	1.3 ± 1.0
Rutin	56 ± 0.8 <sup>#</sup>	52 ± 0.45 <sup>#</sup>	36.6 ± 0.53 <sup>#</sup>	35 ± 0.32 <sup>#</sup>	22 ± 1.8 <sup>#</sup>	1.2 ± 1.1 <sup>#</sup>
CCl <sub>4</sub>	71.2 ± 0.68 <sup>*</sup>	69 ± 0.58 <sup>*</sup>	20.8 ± 0.8 <sup>*</sup>	54 ± 0.8 <sup>*</sup>	48 ± 3.2 <sup>*</sup>	5.3 ± 1.2 <sup>*</sup>
CCl <sub>4</sub> + rutin	52 ± 0.52 <sup>#</sup>	48 ± 0.90 <sup>#</sup>	38 ± 0.78 <sup>#</sup>	32 ± 0.9 <sup>#</sup>	25 ± 2.1 <sup>**</sup>	1.5 ± 1.5 <sup>#</sup>

Mean ± SE (*n* = 10); HDL: high density lipoprotein; LDL: low density lipoprotein.

<sup>\*</sup>indicates significance from the control group.

<sup>#</sup>indicates significance from the CCl<sub>4</sub> group.




FIGURE 1: The effect of CCl<sub>4</sub>, rutin, and their combination on the mRNA (a) and protein (b) expression levels of glutathione peroxidase in rat liver. Data were presented as mean ± SEM (*n* = 10). \*, #, and \$ indicate significant change from control, rutin, and CCl<sub>4</sub> plus rutin, respectively, at *P* < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test.

significant changes in liver enzymes compared to the control group. However, administration of rutin with CCl<sub>4</sub> resulted in reversal of hepatic damage biomarker induced by CCl<sub>4</sub> to its normal values.

In the CCl<sub>4</sub> group serum cholesterol, triglycerides, and LDL levels were significantly increased by 42%, 21%, and 60%, respectively, while HDL concentration was decreased by 39% compared to the control group. Administration of rutin alone resulted in nonsignificant change in lipid profile compared to the control group. Interestingly, rutin supplementation in combination with CCl<sub>4</sub> resulted in complete reversal of lipid profile levels induced by CCl<sub>4</sub> to its normal values (Table 2).

**3.2. The Effect of CCl<sub>4</sub>, Rutin, and Their Combination on TBAR and H<sub>2</sub>O<sub>2</sub>.** The effect of CCl<sub>4</sub>, rutin, and their combination on lipid peroxidation biomarkers TBAR and H<sub>2</sub>O<sub>2</sub>, was shown in Table 2. In the CCl<sub>4</sub> group, there was significant increase in TBAR by 167% (*P* < 0.0001) and in H<sub>2</sub>O<sub>2</sub> by 308% (*P* < 0.01) compared to the control group. Administration of rutin alone showed nonsignificant changes in TBAR and

H<sub>2</sub>O<sub>2</sub> levels compared to the control group. However, CCl<sub>4</sub> with rutin administration resulted in complete reversal of TBAR and H<sub>2</sub>O<sub>2</sub> levels induced by CCl<sub>4</sub> to their normal values. These changes in TBAR and H<sub>2</sub>O<sub>2</sub> levels were significant compared to CCl<sub>4</sub> group (*P* < 0.0001).

**3.3. The Effect of CCl<sub>4</sub>, Rutin, and Their Combination on the Antioxidant Gene Expression.** To investigate the effect of CCl<sub>4</sub>, rutin, and their combination on the oxidative stress, the GPx, CAT, and GST genes expression levels were measured in liver tissues using real time RT-PCR and western blot analysis (Figures 1, 2, and 3). In the CCl<sub>4</sub> group, GPx gene expression was significantly decreased in mRNA level by 2-fold (Figure 1(a)) and in protein level by 80% (Figure 1(b)); the CAT gene expression level was significantly decreased in mRNA by 5-fold (Figure 2(a)) and in protein level by 75% (Figure 2(b)) compared to the control group. Furthermore, in liver tissue, CCl<sub>4</sub> significantly decreased the GST expression levels by 2.9-fold in mRNA (Figure 3(a)) and by 67% in protein level compared to the control group. Administration




FIGURE 2: The effect of CCl<sub>4</sub>, rutin, and their combination on the mRNA (a) and protein (b) expression levels of catalase in rat liver. Data were presented as mean ± SEM (*n* = 10). \*, #, and \$ indicate significant change from control, rutin, and CCl<sub>4</sub> plus rutin, respectively, at *P* < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test.




FIGURE 3: The effect of CCl<sub>4</sub>, rutin, and their combination on the mRNA (a) and protein (b) expression levels of glutathione S transferase in rat liver. Data were presented as mean ± SEM (*n* = 10). \*, #, and \$ indicate significant change from control, rutin, and CCl<sub>4</sub> plus rutin, respectively, at *P* < 0.05 using ANOVA followed by Tukey-Kramer as a post ANOVA test.

of rutin alone resulted in nonsignificant increase in GPx, CAT, and GST mRNA expression levels compared to the control group. Rutin supplementation in combination with CCl<sub>4</sub> resulted in complete reversal of CCl<sub>4</sub> aberrant effect on the antioxidant genes expression levels (mRNA and

protein) to their normal values as in the control group. These reversal changes were observed as significant increase in GPx, CAT, and GST mRNA expression by 2.4-, 4-, and 4.4-fold and protein level by 85%, 88%, and 64% expression levels, respectively, compared to CCl<sub>4</sub> group.




FIGURE 4: The effect of CCl<sub>4</sub>, rutin, and their combination on the PON-1 mRNA (a) and protein (b) expression levels in rat liver. Data were presented as mean  $\pm$  SEM ( $n = 10$ ). \*, #, and \$ indicate significant change from control, rutin, and CCl<sub>4</sub> plus rutin, respectively, at  $P < 0.05$  using ANOVA followed by Tukey-Kramer as a post ANOVA test.

**3.4. The Effect of CCl<sub>4</sub>, Rutin, and Their Combination on PON1 Gene Expression.** Figure 4 showed the effect of CCl<sub>4</sub>, rutin, and their combination on the PON-1 gene expression level in liver tissue. In the CCl<sub>4</sub> group significant reduction in the mRNA by 4-fold and protein by 50% expression level of PON-1 gene was observed ( $P < 0.02$ ) (Figures 4(a) and 4(b)) compared to the control group. The supplementation of rutin in combination with CCl<sub>4</sub> showed significant increase in the gene expression level by 4.8-fold ( $P < 0.02$ ) compared to the CCl<sub>4</sub> group, whereas the protein level in CCl<sub>4</sub>-rutin group was significantly decreased compared to both control and rutin groups. In the rutin group, there was a significant increase in the PON-1 gene expression level compared to the control group ( $P < 0.05$ ).

**3.5. The Effect of CCl<sub>4</sub>, Rutin, and Their Combination on the PON-3 Gene Expression Level.** The effect of CCl<sub>4</sub>, rutin, and their combination on PON-3 expression level was shown in Figure 5. The administration of CCl<sub>4</sub> alone resulted in a decrease in the expression level of PON-3 mRNA by 4-fold (Figure 5(a)) and protein by 52% (Figure 5(b)) ( $P < 0.03$ ) compared to the control group. The administration of rutin in combination with CCl<sub>4</sub> showed a significant increase in the mRNA expression level by 1.8- ( $P < 0.03$ ) and 7.2- ( $P < 0.001$ ) fold compared to the control and CCl<sub>4</sub> groups, respectively.

**3.6. The Effect of CCl<sub>4</sub>, Rutin, and Their Combination on ABCA1 Gene Expression.** Figure 6 showed the effect of CCl<sub>4</sub>, rutin, and their combination on the expression level of ABCA1 gene. In the CCl<sub>4</sub> group, ABCA1 was significantly decreased in mRNA by 2.5-fold expression (Figure 6(a)) and in protein level by 58% (Figure 6(b)) compared to the control

group ( $P < 0.038$ ). The administration of rutin in combination with CCl<sub>4</sub> resulted in significant increase in the mRNA by 3.25-fold and protein expression levels by 25% of ABCA1 gene compared to CCl<sub>4</sub> group ( $P < 0.009$ ). In CCl<sub>4</sub> with rutin supplementation, the increase in ABCA1 mRNA was insignificant but the protein level was significantly compared to the control group.

**3.7. The Effect of CCl<sub>4</sub>, Rutin, and Their Combination on PPAR- $\delta$  Gene Expression.** Figure 7 showed the effect of CCl<sub>4</sub>, rutin, and their combination on PPAR- $\delta$  gene expression in liver tissues. In the CCl<sub>4</sub> group, the PPAR- $\delta$  gene expression was significantly decreased in mRNA by 1.6-fold (Figure 7(a)) and protein by 56% (Figure 7(b)) compared to the control group. The administration of rutin in combination with CCl<sub>4</sub> showed significant increase in the PPAR- $\delta$  expression level mRNA 3-fold ( $P < 0.002$ ) and protein by 58% compared to CCl<sub>4</sub> groups. The increase in mRNA PPAR- $\delta$  in CCl<sub>4</sub>-rutin group was significantly compared to the control group ( $P < 0.03$ ).

**3.8. The Effect of CCl<sub>4</sub>, Rutin, and Their Combination on MCP-1 Gene Expression.** The effect of CCl<sub>4</sub>, rutin, and their combination on MCP-1 gene expression in liver tissues was shown in Figure 8. In the CCl<sub>4</sub> group, the expression level of MCP-1 was significantly increased in mRNA by 2.1-fold and protein by 34% compared to the control group. In the CCl<sub>4</sub>-rutin group a significant decrease was observed in the MCP-1 mRNA and protein expression. This decrease in the expression level was statistically significant compared to CCl<sub>4</sub> group. In the rutin group, the MCP-1 mRNA expression level




FIGURE 5: The effect of CCl<sub>4</sub>, rutin, and their combination on the PON-3 mRNA (a) and protein (b) expression levels in rat liver. Data were presented as mean  $\pm$  SEM ( $n = 10$ ). \*, #, and \$ indicate significant change from control, rutin, and CCl<sub>4</sub> plus rutin, respectively, at  $P < 0.05$  using ANOVA followed by Tukey-Kramer as a post ANOVA test.




FIGURE 6: The effect of CCl<sub>4</sub>, rutin, and their combination on the mRNA (a) and protein (b) expression levels of ABCA1 gene in rat liver. Data were presented as mean  $\pm$  SEM ( $n = 10$ ). \*, #, and \$ indicate significant change from control, rutin, and CCl<sub>4</sub> plus rutin, respectively, at  $P < 0.05$  using ANOVA followed by Tukey-Kramer as a post ANOVA test.

was insignificantly increased compared to the control group ( $P < 0.3$ ).

#### 4. Discussion

Liver diseases caused by viral infection or other hepatotoxic agent are highly associated with severe damage [28, 29].

Hepatic inflammation is considered as early stage of fibrosis, which can progress to extensive fibrosis and cirrhosis. Carbon tetrachloride is widely used to investigate liver injury associated with oxidative stress and free radicals. Reactive oxygen species induced by CCl<sub>4</sub> not only cause direct tissue damage but also initiate inflammation [30]. Chemoprevention and dietary modification are effective against oxidative stress




FIGURE 7: The effect of CCl<sub>4</sub>, rutin, and their combination on the mRNA (a) and protein (b) expression levels of PPAR-δ in rat liver. Data were presented as mean ± SEM ( $n = 10$ ). \*, #, and \$ indicate significant change from control, rutin, and CCl<sub>4</sub> plus rutin, respectively, at  $P < 0.05$  using ANOVA followed by Tukey-Kramer as a post ANOVA test.




FIGURE 8: The effect of CCl<sub>4</sub>, rutin, and their combination on the mRNA (a) and protein (b) MCP-1 expression levels in rat liver. Data were presented as mean ± SEM ( $n = 10$ ). \*, #, and \$ indicate significant change from control, rutin, and CCl<sub>4</sub> plus rutin, respectively, at  $P < 0.05$  using ANOVA followed by Tukey-Kramer as a post ANOVA test.

and are now the focus of several researches [31]. Rutin had hepatoprotective effect against agents-induced liver injuries.

The present study showed that CCl<sub>4</sub> significantly increased the ALT and AST serum levels. The increase in the liver enzymes resulted in acute hepatocyte injuries caused by CCl<sub>4</sub> [32]. In the current study, rutin supplementation in combination with CCl<sub>4</sub> significantly restored the AST

and ALT levels to the normal values. Therefore, rutin may have the ability to protect liver from CCl<sub>4</sub>-induced injury. Similarly, previous study reported the protective effect of flavonoid compounds against CCl<sub>4</sub>-induced hepatotoxicity [19].

The CCl<sub>4</sub>-induced oxidative stress causes DNA mutation and increases fibroblastic activity leading to liver cirrhosis

and carcinoma. In the present study, the aberrations in lipid profile induced by  $\text{CCl}_4$  were restored to normal values with rutin treatment. Lipid alteration is a causal factor for oxidative stress that resulted from increase in ROS production and reduction in antioxidant enzymes [33]. Lipid peroxidation and ROS impaired the respiratory chain in hepatocyte via oxidative damage of mitochondrial DNA. The rutin protective effect is due to the ability to chelate metal ions and minerals hence decreasing oxidative stress and lowering lipid profile [34]. This hypothesis is in agreement with another study that found hepatoprotective effects of some plant bioactive compounds against  $\text{CCl}_4$ -induced hepatic injury in rats [35]. Lipid peroxidation is characterized by imbalance between oxidant-antioxidant and ROS induced by  $\text{CCl}_4$ .

Glutathione in liver provides the first line of defense by scavenging ROS. The decrease in glutathione concentration may be due to NADPH reduction or GSH utilization in exclusion of peroxides [36]. In the current study, lipid peroxidation was increased in  $\text{CCl}_4$  group by increasing TBAR serum level. This will cause  $\text{H}_2\text{O}_2$  elevation that could further stimulate lipid peroxidation. Similarly, another study showed that  $\text{CCl}_4$  is an independent risk factor for increasing lipid peroxidation and decreases activity of antioxidant enzymes which lead to DNA damage [19]. In the current study, administration of rutin with  $\text{CCl}_4$  markedly reduced the DNA damage via reduction in oxidative stress, which agrees with previous study [37].

Cell damage, induced by oxidative stress, is attenuated by antioxidant enzyme. When the imbalance between ROS production and antioxidant defense is lost, oxidative stress occurred through a series of events which deregulates the cellular functions leading to various pathological conditions [38]. Glutathione peroxidase, glutathione S transferase, and catalase enzymes are superoxide ion and  $\text{H}_2\text{O}_2$  scavengers that protect cells from oxidative damage [39]. Catalase removes the peroxide produced by superoxide dismutase and catalyses the breakdown of  $\text{H}_2\text{O}_2$  to water and oxygen. The current study showed significant decrease in GPx, GST, and CAT gene expression levels in liver tissues in association with increase in serum TBAR and  $\text{H}_2\text{O}_2$  in  $\text{CCl}_4$  group and is in agreement with another study [39]. Lipid oxidation product (TBAR) and antioxidant genes GSP, CAT, and GST aberrations induced by  $\text{CCl}_4$  were restored to normal levels by rutin treatment.

The PON1 and PON3 are efficient in reducing LDL oxidation [40]. The decreased expression and activity of PON1 have been associated with chronic liver disease [41]. The present data revealed significant decrease in PON1 and PON3 expression levels in  $\text{CCl}_4$ -group in liver tissues. PON1 and PON3 are mainly synthesized and expressed in liver [42, 43]. In the present study, the decrease in PON1 and PON3 expression may be due to the hepatic dysfunction induced by  $\text{CCl}_4$  toxicity. PON1 protein, an antioxidant, is localized on HDL surface and stimulates the macrophage cholesterol efflux. The decrease in PON1 expression and activity could be a consequence of altered synthesis and/or secretion of HDL. This alteration in chronic liver disease is associated with decrease in hepatic lecithin cholesterol acyl transferase activity [44].

Carbon tetrachloride metabolism produces high reactive free radicals that react with sulfhydryl groups, such as glutathione and protein thiols [45]. Antioxidant activity of PON1 is associated with its  $-\text{SH}$  groups; therefore, the reduction in PON1 antioxidant activity might be due to alteration in nature and number of free thiol groups in its molecule [46]. These data support the idea that administration of  $\text{CCl}_4$  induces oxidative stress by increasing lipid peroxidation which in turn decreases PON1 expression.

The hepatoprotective effect of PON3 was closely interrelated to its lactonase activities and antioxidant capabilities. PON3 can reduce oxidative products via preventing oxidation and suppressing the propagation of oxidation by destroying lipid hydroperoxides in oxidized LDL [47, 48]. In the current study, PON1 and PON3 genes were significantly increased in rutin supplementation with  $\text{CCl}_4$  treated rats. Data from this study suggested that PON1 and PON3 might have protective effect on hepatotoxicity induced by  $\text{CCl}_4$  via hydrolyzing specific oxidized lipids.

The MCP-1 production by oxidized lipids and lipoproteins is important in inflammation [49]. PON1 inhibited the production of MCP-1 induced by oxidized LDL [50]. PON1 and MCP-1 are collaborated in regulating inflammatory processes. Increased MCP-1 concentration and decreased PON1 activity are often observed in conditions involving oxidative stress [51]. Aldehyde, the end-product of lipid peroxidation, acts as a regulator to MCP-1 expression in liver [18]. In the present study, a significant increase in MCP-1 gene expression was associated with hepatotoxicity. Similarly, high MCP-1 gene expression level was reported in patients with chronic hepatitis or liver cirrhosis [52, 53] and is correlated with monocyte infiltration in liver. In liver, MCP-1 expression may be initiated or upregulated by circulating lipopolysaccharide or other members of cytokines such as tumor necrosis factor alpha and interleukin-1 [54]. MCP-1 upregulation by oxidizing lipids and lipoproteins is an important factor in initial stages of inflammation [55]. PON1 may act as a barrier against hepatic oxidative stress. This barrier is overcome by exposure to  $\text{CCl}_4$  leading to increase in MCP-1 with severe proinflammatory reaction. PON1 attenuates MCP-1 production induced by oxidized LDL when incubated with epithelial cells [56]. The mechanisms for PON1 and MCP-1 regulation are still unknown.

Peroxisome proliferator-activated receptors (PPARs) are group of nuclear receptor proteins that regulate expression of many genes [57]. PPARs play important roles in metabolism, differentiation, and cancer [58, 59]. PPARs may be involved in regulating and coordinating PON1 and MCP-1 genes expression; PPARs may upregulate PON1 expression in a variety of clinical and experimental situations. Recent evidence indicates that PPAR downregulates MCP-1 expression [50, 60]. In the present study, the PPAR- $\delta$  expression level was significantly decreased in  $\text{CCl}_4$  group compared to the control group. Similarly, another study found that the expression level of PPAR $\delta$  (protein and mRNA) was decreased following  $\text{CCl}_4$  administration [61]. PPAR $\delta$  increases HDL synthesis through activation of ABCA1 gene (the cellular cholesterol exporter) [62]. In the present study, the decrease in ABCA1 gene expression level in  $\text{CCl}_4$  group may explain the highest

level of cholesterol in the same group. Similarly, others found that ABCA1 can mediate the phospholipids and cholesterol efflux and can eliminate HDL biosynthesis in liver [63, 64]. The current study suggested that the decrease in PPAR- $\delta$  gene expression following CCl<sub>4</sub> administration may be associated with decrease in HDL synthesis. PPAR- $\delta$  can upregulate the expression of several antioxidant genes including SOD, CAT, and thioredoxin. The PPAR- $\delta$  suppression is proapoptotic mechanism to eliminate damaged hepatocyte induced by CCl<sub>4</sub> [65].

## 5. Conclusion

In conclusion, the present study suggests that the effect of rutin on CCl<sub>4</sub>-induced hepatotoxicity was mostly by reducing oxidative stress and inflammation in liver. Rutin may be used as an antioxidant via decreasing hepatic stress induced by toxic agents. Also, the present study suggests that PON1, PON3, and PPAR- $\delta$  had protective roles against liver disease.

## Conflict of Interests

The authors declare that they have no conflict of interests.

## Authors' Contribution

Mohamed M. Hafez designed and performed the study and wrote the paper. Othman A. AL-Shabanah, Naif O. Al-Harbi, Mohamed M. Al-Harbi, Salim S. Al-Rejaie, Saad M. Alsurayea, and Mohamed M. Sayed-Ahmed revised the paper.

## Acknowledgment

The authors thank the Deanship of Scientific Research at KSU for funding this work through the Research Group Project no. RGP-VPP-142.

## References

- [1] K. R. Thilakchand, R. T. Mathai, P. Simon et al., "Hepatoprotective properties of the Indian gooseberry (*Emblica officinalis* Gaertn): a review," *Food & Function*, vol. 4, no. 10, pp. 1431–1441, 2013.
- [2] F. H. Kamisan, F. Yahya, and S. S. Mamat, "Effect of methanol extract of *dicranopteris linearis* against carbon tetrachloride-induced acute liver injury in rats," *BMC Complementary and Alternative Medicine*, vol. 14, no. 1, article 123, 2014.
- [3] D.-Z. Hsu, Y.-H. Li, P.-Y. Chu, S.-P. Chien, Y.-C. Chuang, and M.-Y. Liu, "Attenuation of endotoxin-induced oxidative stress and multiple organ injury by 3,4-methylenedioxyphenol in rats," *Shock*, vol. 25, no. 3, pp. 300–305, 2006.
- [4] R. Kohen and A. Nyska, "Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification," *Toxicologic Pathology*, vol. 30, no. 6, pp. 620–650, 2002.
- [5] O. A. Adesanoye and E. O. Farombi, "Hepatoprotective effects of *Vernonia amygdalina* (astereaceae) in rats treated with carbon tetrachloride," *Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft fur Toxikologische Pathologie*, vol. 62, no. 2, pp. 197–206, 2010.
- [6] R. Blomhoff, "Dietary antioxidants and cardiovascular disease," *Current Opinion in Lipidology*, vol. 16, no. 1, pp. 47–54, 2005.
- [7] S. R. Pinnell, "Cutaneous photodamage, oxidative stress, and topical antioxidant protection," *Journal of the American Academy of Dermatology*, vol. 48, no. 1, pp. 1–22, 2003.
- [8] V. M. Abazov, B. Abbott, M. Abolins et al., "Search for neutral supersymmetric Higgs Bosons in multijet events at sqrt[s]=1.96 TeV," *Physical Review Letters*, vol. 95, no. 15, Article ID 151801, 2005.
- [9] L. G. Costa, A. Vitalone, T. B. Cole et al., "Modulation of paraoxonase (PON1) activity," *Biochemical pharmacology*, vol. 69, no. 4, pp. 541–550, 2005.
- [10] S. T. Reddy, D. J. Wadleigh, V. Grijalva et al., "Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 21, no. 4, pp. 542–547, 2001.
- [11] D. I. Draganov, "Human PON3, effects beyond the HDL: clues from human PON3 transgenic mice," *Circulation Research*, vol. 100, no. 8, pp. 1104–1105, 2007.
- [12] C. J. Ng, D. M. Shih, S. Y. Hama, N. Villa, M. Navab, and S. T. Reddy, "The paraoxonase gene family and atherosclerosis," *Free Radical Biology and Medicine*, vol. 38, no. 2, pp. 153–163, 2005.
- [13] D. Seo and P. Goldschmidt-Clermont, "The paraoxonase gene family and atherosclerosis," *Current Atherosclerosis Reports*, vol. 11, no. 3, pp. 182–187, 2009.
- [14] S. T. Reddy, A. Devarajan, N. Bourquard et al., "Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis?" *Current Opinion in Lipidology*, vol. 19, no. 4, pp. 405–408, 2008.
- [15] C. J. Ng, D. J. Wadleigh, A. Gangopadhyay et al., "Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein," *The Journal of Biological Chemistry*, vol. 276, no. 48, pp. 44444–44449, 2001.
- [16] K. J. Simpson, N. C. Henderson, C. L. Bone-Larson, N. W. Lukacs, C. M. Hogaboam, and S. L. Kunkel, "Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles," *Clinical Science*, vol. 104, no. 1, pp. 47–63, 2003.
- [17] J. Marsillach, N. Bertran, J. Camps et al., "The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease," *Clinical Biochemistry*, vol. 38, no. 12, pp. 1138–1140, 2005.
- [18] M. J. Czaja, A. Geerts, J. Xu, P. Schmiedeberg, and Y. Ju, "Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease," *Journal of Leukocyte Biology*, vol. 55, no. 1, pp. 120–126, 1994.
- [19] R. A. Khan, M. R. Khan, and S. Sahreen, "CCl<sub>4</sub>-induced hepatotoxicity: protective effect of rutin on p53, CYP2E1 and the antioxidative status in rat," *BMC Complementary and Alternative Medicine*, vol. 12, article 178, 2012.
- [20] H. T. M. Hefnawy and M. F. Ramadan, "Protective effects of *Lactuca sativa* ethanolic extract on carbon tetrachloride induced oxidative damage in rats," *Asian Pacific Journal of Tropical Disease*, vol. 3, no. 4, pp. 277–285, 2013.
- [21] M. Ogeturk, I. Kus, N. Colakoglu et al., "Caffeic acid phenethyl ester protects kidneys against carbon tetrachloride toxicity in rats," *Journal of Ethnopharmacology*, vol. 97, no. 2, pp. 273–280, 2005.

- [22] J. D. Potter, "Cancer prevention: epidemiology and experiment," *Cancer Letters*, vol. 114, no. 1-2, pp. 7-9, 1997.
- [23] A. L. Huntley, "The health benefits of berry flavonoids for menopausal women: cardiovascular disease, cancer and cognition," *Maturitas*, vol. 63, no. 4, pp. 297-301, 2009.
- [24] A. J. Alonso-Castro, F. Dominguez, and A. Garcia-Carranca, "Rutin exerts antitumor effects on nude mice bearing SW480 tumor," *Archives of Medical Research*, vol. 44, no. 5, pp. 346-351, 2013.
- [25] K. Sikder, S. B. Kesh, N. Das et al., "The high antioxidative power of quercetin (aglycone flavonoid) and its glycone (rutin) avert high cholesterol diet induced hepatotoxicity and inflammation in Swiss albino mice," *Food & Function*, vol. 5, no. 6, pp. 1294-1303, 2014.
- [26] W. L. Bear and R. W. Teel, "Effects of citrus flavonoids on the mutagenicity of heterocyclic amines and on cytochrome P450 1A2 activity," *Anticancer Research*, vol. 20, no. 5B, pp. 3609-3614, 2000.
- [27] S.-S. Chen, J. Gong, F.-T. Liu, and U. Mohammed, "Naturally occurring polyphenolic antioxidants modulate IgE-mediated mast cell activation," *Immunology*, vol. 100, no. 4, pp. 471-480, 2000.
- [28] F. Tacke, T. Luedde, and C. Trautwein, "Inflammatory pathways in liver homeostasis and liver injury," *Clinical Reviews in Allergy & Immunology*, vol. 36, no. 1, pp. 4-12, 2009.
- [29] C. K. Tseng, C. K. Lin, H. W. Chang et al., "Aqueous extract of *Gracilaria tenuistipitata* suppresses LPS-induced NF-kappaB and MAPK activation in RAW 264.7 and rat peritoneal macrophages and exerts hepatoprotective effects on carbon tetrachloride-treated rat," *PLoS ONE*, vol. 9, no. 1, Article ID e86557, 2014.
- [30] H. Y. Kim, J. Park, K. H. Lee et al., "Ferulic acid protects against carbon tetrachloride-induced liver injury in mice," *Toxicology*, vol. 282, no. 3, pp. 104-111, 2011.
- [31] O. I. Aruoma, "Methodological considerations for characterizing potential antioxidant actions of bioactive components in plant foods," *Mutation Research*, vol. 523-524, pp. 9-20, 2003.
- [32] Y. Y. Hu, C. H. Liu, R. P. Wang et al., "Protective actions of salvianolic acid A on hepatocyte injured by peroxidation in vitro," *World Journal of Gastroenterology (WJG)*, vol. 6, no. 3, pp. 402-404, 2000.
- [33] S. Tsimikas and Y. I. Miller, "Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications," *Current Pharmaceutical Design*, vol. 17, no. 1, pp. 27-37, 2011.
- [34] J. R. Zhou and J. W. Erdman Jr., "Phytic acid in health and disease," *Critical Reviews in Food Science and Nutrition*, vol. 35, no. 6, pp. 495-508, 1995.
- [35] S. Sreelatha, P. R. Padma, and M. Umadevi, "Protective effects of *Coriandrum sativum* extracts on carbon tetrachloride-induced hepatotoxicity in rats," *Food and Chemical Toxicology*, vol. 47, no. 4, pp. 702-708, 2009.
- [36] P. Yadav, S. Sarkar, and D. Bhatnagar, "Action of capparidic acid against alloxan-induced oxidative stress and diabetes in rat tissues," *Pharmacological Research: The Official Journal of the Italian Pharmacological Society*, vol. 36, no. 3, pp. 221-228, 1997.
- [37] M. R. Khan, W. Rizvi, G. N. Khan et al., "Carbon tetrachloride-induced nephrotoxicity in rats: protective role of *digera muricata*," *Journal of Ethnopharmacology*, vol. 122, no. 1, pp. 91-99, 2009.
- [38] O. Blokhina, E. Virolainen, and K. V. Fagerstedt, "Antioxidants, oxidative damage and oxygen deprivation stress: a review," *Annals of Botany*, vol. 91, pp. 179-194, 2003.
- [39] M. D. Scott, B. H. Lubin, L. Zuo et al., "Erythrocyte defense against hydrogen peroxide: preeminent importance of catalase," *The Journal of Laboratory and Clinical Medicine*, vol. 118, no. 1, pp. 7-16, 1991.
- [40] M. Aviram and M. Rosenblat, "Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development," *Free Radical Biology & Medicine*, vol. 37, no. 9, pp. 1304-1316, 2004.
- [41] J. Camps, J. Marsillach, and J. Joven, "Measurement of serum paraoxonase-1 activity in the evaluation of liver function," *World Journal of Gastroenterology*, vol. 15, no. 16, pp. 1929-1933, 2009.
- [42] C. Zhang, W. Peng, X. Jiang et al., "Transgene expression of human PON1 Q in mice protected the liver against CCl4-induced injury," *The Journal of Gene Medicine*, vol. 10, no. 1, pp. 94-100, 2008.
- [43] W. Peng, X. Jiang, L. Haiqin et al., "Protective effects of transgene expressed human PON3 against CCl4-induced subacute liver injury in mice," *Biomedicine & Pharmacotherapy*, vol. 63, no. 8, pp. 592-598, 2009.
- [44] E. A. Karavia, D. J. Papachristou, and I. Kotsikogianni, "Lecithin/cholesterol acyltransferase modulates diet-induced hepatic deposition of triglycerides in mice," *The Journal of Nutritional Biochemistry*, vol. 24, no. 3, pp. 567-577, 2013.
- [45] L. Jaouad, C. de Guise, H. Berrougui et al., "Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups," *Atherosclerosis*, vol. 185, no. 1, pp. 191-200, 2006.
- [46] W. J. Brattin, E. A. Glende Jr., and R. O. Recknagel, "Pathological mechanisms in carbon tetrachloride hepatotoxicity," *Journal of Free Radicals in Biology & Medicine*, vol. 1, no. 1, pp. 27-38, 1985.
- [47] H. Lu, J. Zhu, Y. Zang et al., "Cloning, high level expression of human paraoxonase-3 in Sf9 cells and pharmacological characterization of its product," *Biochemical Pharmacology*, vol. 70, no. 7, pp. 1019-1025, 2005.
- [48] H. Ohkawa, N. Ohishi, and K. Yagi, "Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction," *Analytical Biochemistry*, vol. 95, no. 2, pp. 351-358, 1979.
- [49] G. Rossoni, F. Berti, F. Trento et al., "Defibrotide normalizes cardiovascular function hampered by established atherosclerosis in the rabbit," *Thrombosis Research*, vol. 97, no. 2, pp. 29-38, 2000.
- [50] A. Rull, J. Camps, C. Alonso-Villaverde et al., "Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (or CCL2) in the regulation of metabolism," *Mediators of Inflammation*, vol. 2010, Article ID 326580, 11 pages, 2010.
- [51] L. Ho, W. Zhao, K. Dams-O'Connor et al., "Elevated plasma MCP-1 concentration following traumatic brain injury as a potential "predisposition" factor associated with an increased risk for subsequent development of Alzheimer's disease," *Journal of Alzheimer's Disease: JAD*, vol. 31, no. 2, pp. 301-313, 2012.
- [52] M. S. Esplin, M. R. Peltier, S. Hamblin et al., "Monocyte chemoattractant protein-1 expression is increased in human gestational tissues during term and preterm labor," *Placenta*, vol. 26, no. 8-9, pp. 661-671, 2005.
- [53] A. Kharfi and A. Akoum, "Correlation between decreased type-II interleukin-1 receptor and increased monocyte chemotactic protein-1 expression in the endometrium of women with endometriosis," *American Journal of Reproductive Immunology*, vol. 45, no. 4, pp. 193-199, 2001.

- [54] T. Tan, C. Ozbalci, B. Brugger et al., "Mcp1 and Mcp2, two novel proteins involved in mitochondrial lipid homeostasis," *Journal of Cell Science*, vol. 126, no. 16, pp. 3563–3574, 2013.
- [55] R. Ross, "The pathogenesis of atherosclerosis: a perspective for the 1990s," *Nature*, vol. 362, no. 6423, pp. 801–809, 1993.
- [56] B. Mackness, D. Hine, Y. Liu et al., "Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells," *Biochemical and Biophysical Research Communications*, vol. 318, no. 3, pp. 680–683, 2004.
- [57] S. Aleshin and G. Reiser, "Role of the peroxisome proliferator-activated receptors (PPAR)-alpha, beta/delta and gamma triad in regulation of reactive oxygen species signaling in brain," *Biological Chemistry*, vol. 394, no. 12, pp. 1553–1570, 2013.
- [58] P. Andreeva-Gateva, "Peroxisome proliferator activated receptors PPARs: their role in carbohydrate and lipid metabolism," *Annales de Biologie Clinique*, vol. 61, no. 3, pp. 295–303, 2003.
- [59] A. Belfiore, M. Genua, and R. Malaguarnera, "PPAR- $\gamma$  agonists and their effects on IGF-I receptor signaling: implications for cancer," *PPAR Research*, vol. 2009, Article ID 830501, 18 pages, 2009.
- [60] J. Camps, A. Garcia-Heredia, A. Rull et al., "PPARs in regulation of paraoxonases: control of oxidative stress and inflammation pathways," *Control of Oxidative Stress and Inflammation Pathways*, vol. 2012, Article ID 616371, 10 pages, 2012.
- [61] W. Peng, C. Zhang, H. Lv et al., "Comparative evaluation of the protective potentials of human paraoxonase 1 and 3 against CCl<sub>4</sub>-induced liver injury," *Toxicology Letters*, vol. 193, no. 2, pp. 159–166, 2010.
- [62] C. Furnsinn, T. M. Willson, and B. Brunmair, "Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport," *Diabetologia*, vol. 50, no. 1, pp. 8–17, 2007.
- [63] Y. Zheng, A. B. Patel, V. Narayanaswami et al., "Retention of alpha-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency," *Biochemical and Biophysical Research Communications*, vol. 441, no. 1, pp. 71–76, 2013.
- [64] E. Reboul, F. M. Dyka, F. Quazi et al., "Cholesterol transport via ABCA1: new insights from solid-phase binding assay," *Biochimie*, vol. 95, no. 4, pp. 957–961, 2013.
- [65] Y. Fan, Y. Wang, Z. Tang et al., "Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 2, pp. 315–321, 2008.



**Hindawi**  
Submit your manuscripts at  
<http://www.hindawi.com>

